Foundayo GLP-1 Pill: FDA Needs More Data
Podcast: On The Pen GLP-1 NewsPublished On: Tue Apr 14 2026
Description: Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require refrigeration and is easier to scale for widespread use. Dave highlights the ongoing questions that linger about the drugs approval as it relates to liver safety.
The note was deleted
The note was saved
Your message was sent